Clinical Significance of Indeterminate Antibody to Hepatitis C in Cancer Patients
Journal of Viral Hepatitis · 2026-12 · 33 (12)
DOI: 10.1111/jvh.70257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 31.10.2026. Verfasst von Joanne Arvelaez Pascucci und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Hepatitis C Antibodies, Hepatitis C, Neoplasms. Die Arbeit nennt 7 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Most patients with cancer are screened for hepatitis C virus (HCV) infection using an antibody to HCV (anti‐HCV) test. However, the importance of an indeterminate anti‐HCV result is unknown. We investigated the clinical significance of an indeterminate anti‐HCV result in cancer patients. We conducted a retrospective cohort study of cancer patients screened for HCV infection using ARCHITECT Anti‐HCV at our institution between October 2016 and July 2024. Patients were categorized based on their anti‐HCV results as patients with indeterminate anti‐HCV and undetectable HCV‐RNA in the absence of HCV treatment, and patients with reactive anti‐HCV and chronic infection. We compared the two groups using univariable analyses and multivariable logistic regression analysis. Of the 112,180 patients screened with anti‐HCV, 114 (0.1%) had indeterminate results; 101 of them with confirmed cancer were further analysed. Anti‐HCV testing was repeated in 24 (24%) patients; most (84%) had non‐reactive (46%) or indeterminate (38%) results. Among the 101 patients with indeterminate anti‐HCV, 98 (97%) did not have proven HCV infection, but 3 (3%) had HCV infection. Multivariable analysis showed that male sex (adjusted odds ratio [aOR] 2.22, 95% confidence interval [CI] 1.40–3.53, p < 0.001), age ≥ 60 years (aOR 1.61, 95% CI 1.01–2.56, p = 0.046), hepatitis B or HIV coinfection (aOR 3.13, 95% CI 1.21–8.11, p = 0.019) and cirrhosis (aOR 6.67, 95% CI 2.05–21.69, p = 0.002) were more likely to have chronic than an indeterminate anti‐HCV result. Indeterminate anti‐HCV results are uncommon in cancer patients and rarely indicate HCV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Joanne Arvelaez Pascucci, Khalis Mustafayev, Eduardo Yepez Guevara, Harrys A Torres
Zitieren
APA
Pascucci, J. A., Mustafayev, K., Jiang, Y., Raad, I., Guevara, E. Y., & Torres, H. A. (2026). Clinical Significance of Indeterminate Antibody to Hepatitis C in Cancer Patients. Journal of Viral Hepatitis, 33(12). https://doi.org/10.1111/jvh.70257
Vancouver
Pascucci JA, Mustafayev K, Jiang Y, Raad I, Guevara EY, Torres HA. Clinical Significance of Indeterminate Antibody to Hepatitis C in Cancer Patients. Journal of Viral Hepatitis. 2026;33(12). doi:10.1111/jvh.70257
BibTeX
@article{Pascucci2026,
author = {Pascucci, Joanne Arvelaez and Mustafayev, Khalis and Jiang, Ying and Raad, Issam and Guevara, Eduardo Yepez and Torres, Harrys A},
title = {Clinical Significance of Indeterminate Antibody to Hepatitis C in Cancer Patients},
journal = {Journal of Viral Hepatitis},
year = {2026},
volume = {33},
number = {12},
doi = {10.1111/jvh.70257}
}
EUVIMED